Cargando…

培美曲塞在晚期非小细胞肺癌二线及以上治疗中的疗效分析

BACKGROUND AND OBJECTIVE: Pemetrexed is a standard second-line therapy in advanced non-small cell lung cancer (NSCLC). Currently, cytotoxic treatments beyond second-line therapy are not available. This study evaluated the efficacy and safety of pemetrexed as a salvage regimen in heavily pretreated p...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999869/
https://www.ncbi.nlm.nih.gov/pubmed/22429582
http://dx.doi.org/10.3779/j.issn.1009-3419.2012.03.08
_version_ 1783331537049092096
collection PubMed
description BACKGROUND AND OBJECTIVE: Pemetrexed is a standard second-line therapy in advanced non-small cell lung cancer (NSCLC). Currently, cytotoxic treatments beyond second-line therapy are not available. This study evaluated the efficacy and safety of pemetrexed as a salvage regimen in heavily pretreated patients with NSCLC. METHODS: Clinical data on 37 patients with advanced NSCLC who received pemetrexed as second-line therapy or beyond in Cancer Hospital of Peking Union Medical College from Feb 2005 to Sep 2009 were reviewed and analyzed retrospectively. RESULTS: Thirteen patients (35.1%) received pemetrexed as second-line treatment, whereas 24 (64.9%) received it as third-line treatment or beyond. Complete response, partial response, stable disease and progressive disease were noted in 1 (2.7%), 2 (5.4%), 17 (45.9%) and 12 (32.4%) of the patients, respectively, with the disease control rate being 54.1%. The median duration of progression free survival was 8.05 months, whereas that of overall survival was 19.29 months. CONCLUSION: Pemetrexed is efficacious and tolerable as second-line therapy or beyond for advanced NSCLC and should thus be recommended for patients with this disease.
format Online
Article
Text
id pubmed-5999869
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59998692018-07-06 培美曲塞在晚期非小细胞肺癌二线及以上治疗中的疗效分析 Zhongguo Fei Ai Za Zhi 临床经验 BACKGROUND AND OBJECTIVE: Pemetrexed is a standard second-line therapy in advanced non-small cell lung cancer (NSCLC). Currently, cytotoxic treatments beyond second-line therapy are not available. This study evaluated the efficacy and safety of pemetrexed as a salvage regimen in heavily pretreated patients with NSCLC. METHODS: Clinical data on 37 patients with advanced NSCLC who received pemetrexed as second-line therapy or beyond in Cancer Hospital of Peking Union Medical College from Feb 2005 to Sep 2009 were reviewed and analyzed retrospectively. RESULTS: Thirteen patients (35.1%) received pemetrexed as second-line treatment, whereas 24 (64.9%) received it as third-line treatment or beyond. Complete response, partial response, stable disease and progressive disease were noted in 1 (2.7%), 2 (5.4%), 17 (45.9%) and 12 (32.4%) of the patients, respectively, with the disease control rate being 54.1%. The median duration of progression free survival was 8.05 months, whereas that of overall survival was 19.29 months. CONCLUSION: Pemetrexed is efficacious and tolerable as second-line therapy or beyond for advanced NSCLC and should thus be recommended for patients with this disease. 中国肺癌杂志编辑部 2012-03-20 /pmc/articles/PMC5999869/ /pubmed/22429582 http://dx.doi.org/10.3779/j.issn.1009-3419.2012.03.08 Text en 版权所有©《中国肺癌杂志》编辑部2012 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床经验
培美曲塞在晚期非小细胞肺癌二线及以上治疗中的疗效分析
title 培美曲塞在晚期非小细胞肺癌二线及以上治疗中的疗效分析
title_full 培美曲塞在晚期非小细胞肺癌二线及以上治疗中的疗效分析
title_fullStr 培美曲塞在晚期非小细胞肺癌二线及以上治疗中的疗效分析
title_full_unstemmed 培美曲塞在晚期非小细胞肺癌二线及以上治疗中的疗效分析
title_short 培美曲塞在晚期非小细胞肺癌二线及以上治疗中的疗效分析
title_sort 培美曲塞在晚期非小细胞肺癌二线及以上治疗中的疗效分析
topic 临床经验
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999869/
https://www.ncbi.nlm.nih.gov/pubmed/22429582
http://dx.doi.org/10.3779/j.issn.1009-3419.2012.03.08
work_keys_str_mv AT péiměiqūsāizàiwǎnqīfēixiǎoxìbāofèiáièrxiànjíyǐshàngzhìliáozhōngdeliáoxiàofēnxī
AT péiměiqūsāizàiwǎnqīfēixiǎoxìbāofèiáièrxiànjíyǐshàngzhìliáozhōngdeliáoxiàofēnxī
AT péiměiqūsāizàiwǎnqīfēixiǎoxìbāofèiáièrxiànjíyǐshàngzhìliáozhōngdeliáoxiàofēnxī
AT péiměiqūsāizàiwǎnqīfēixiǎoxìbāofèiáièrxiànjíyǐshàngzhìliáozhōngdeliáoxiàofēnxī
AT péiměiqūsāizàiwǎnqīfēixiǎoxìbāofèiáièrxiànjíyǐshàngzhìliáozhōngdeliáoxiàofēnxī